San Francisco, California, United States Related Funds
Funds with similar focus
| Fund Name | Location |
| Banco do Brasil | Brasília, Brazil, Rio Grande do Norte |
| Bank of Sharjah | Dubai, United Arab Emirates |
| GRG Banking | China, Guangdong, Guangzhou |
| IIFL Special Opportunities Fund | - |
| Live Shark Tank | - |
| Nexthera Capital | New York, New York, United States |
| Novelion Therapeutics | British Columbia, Canada, Vancouver |
| Pan Group Investments Pty Ltd | - |
| Park Avenue Capital | California, United States, Whittier |
| Rudin Ventures | - |
| Scientific Health Development Partners | Dallas, Texas, United States |
| Security Bank Corporation | Makati, Manila, Philippines |
| Stow Capital | - |
| The Hodson Trust | - |
| Ulmus Investment | - |
| Yunhe Partners | Beijing, Beijing, China |
| Zhuhai Hengqin Yicheng Guanli Zixun Qiye | China, Guangdong, Zhuhai |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
OncoCell MDx | $22M | 11 Sep 2019 | Corvallis, Oregon, United States | ||
Naurex | $80M | 03 Dec 2014 | Illinois, United States | ||
Naurex | $38M | 17 Dec 2012 | Illinois, United States |
– Glytec announced $21m in financing from SVB, Savitr Capital and other private investors.
– The funding will fuel Glytec’s mission of revolutionizing the role glycemic management plays in the hospital across every department.
– The combined $9m debt financing from SVB and $12m equity investment led by Savitr positions the company to continue its rapid growth by investing in research and development around patient safety, provider workflows and analytics, adding additional talent to its workforce and enhancing integrations with EHRs, mobile apps and other diabetes technology across the continuum of care.
– More than 34m Americans today live with diabetes, 88m live with prediabetes and over one-third of all patients – regardless of a diabetes diagnosis – require insulin during their hospital stay.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
OncoCell MDx | $22M | 11 Sep 2019 | Corvallis, Oregon, United States | ||
Naurex | $80M | 03 Dec 2014 | Illinois, United States | ||
Naurex | $38M | 17 Dec 2012 | Illinois, United States |
